Released Aug 6, 2019, after the close
10-Q filed Aug 6, 2019, 37 days after period end · 0001564590-19-029333
Q2 2019 · 10-Q
Revenue$2.82M$2.82M +174.3% vs Q2 2018+7.0% vs Q1 2019
Net Income-$23.48M-$23.48M N/M vs Q2 2018N/M vs Q1 2019
EPS Diluted-$0.36-$0.36 N/M vs Q2 2018N/M vs Q1 2019
Operating Income-$24,084,000N/M
Operating Cash Flowderived-$20,309,000N/M
Free Cash Flowderived-$22,104,000N/M
Margins · derived
Operating margin-855.0%+1054.0 pt vs Q2 2018
Net margin-833.4%+1080.3 pt vs Q2 2018
What the release said
The release
Same quarter
| Metric | Q2 2019 | Q2 2018 | Q2 2017 | Q2 2016 |
|---|---|---|---|---|
| Revenue | $2.82M | $1.03M | $1.03M | $1.03M |
| Net Income | -$23.48M | -$19.65M | -$9.65M | -$8.41M |
| EPS Diluted | -$0.36 | -$0.37 | -$0.23 | -$0.29 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR